Produktinformation
- 1,9-ethanobenzo[i]quinolizin-14-one, dodecahydro-8a-hydroxy-11-methyl-, (1S,8aS,9S,11R,12aS)-
- Lycopodan-5-one, 12-hydroxy-15-methyl-, (15R)-
Lycodoline is a neuroprotective drug that belongs to the group of matrix-effect drugs. Lycodoline enhances neurotrophic factors, which are proteins that promote the growth and differentiation of neurons. It also reduces chronic kidney disease by inhibiting intramolecular hydrogen bonding at cavity sites in the protein matrix. Lycodoline has been shown to be effective against aconite roots, which are toxic plants that contain a number of alkaloids including aconitine and pseudaconitine. Lycodoline binds to these alkaloids by forming hydrogen bonding interactions with the surface of effector proteins such as anthracyclines and camptothecin derivatives. This binding disrupts the protein-protein interaction, leading to inhibition of DNA synthesis. The LC-MS/MS method is used for determining the concentration of lycodoline in human plasma, which has been found to be inversely proportional to serum creatinine levels.
